Darren Schiller has added a photo to the pool:
Not sure what these bins were celebrating, but I hope they had fun.
Bloor Court, Adelaide CBD
DirtyGlassEye has added a photo to the pool:
For how big it is and how much you can capture from it in both night and day settings, it's a little challenging to get a good shot of Lake Fujikawaguchiko (mouthful of a name). It's essentially just a touristy boat lake, so it's a little challenging to find a usable composition.
Previously I shot around this side of the lake at dusk and that night was very experimental (I already posted the only one I think I can use).
As I was leaving Iyashi two days later, I found myself taking the same road along the other side of the lake. Fuji was starting to disappear behind clouds again but it was still visible enough for the time being.
Near a tunnel I decided to pull over and get one last try at a natural landscape shot on the riverbank, a type of shot I've been a little devoid of in Japan thus far.
Through the dry grass I spotted this pedestal-like rock poking near the shore line with Fuji peaking out behind another forested range. In editing I took a few creative liberties on this in editing, for one, I curved the photo a bit (you can see it in the shore line) and redirected the lighting to Fuji specifically and not the sky. I recentered the light in the dry grass to lead towards the middle as if it was a leading line.
Interestingly, there were two kayakers floating on a turned over raft and waving their oars around (clearly asking for help), cops showed up about 10 minutes later and waited for them to come in. Just an out of the ordinary scenario to witness while trying to set up a shot like this.
An anonymous reader quotes a report from NBC News: The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder. It's the latest move by the Trump administration signaling a shift in policy toward treatments that also give users a high -- coming a day after the Justice Department said it would ease restrictions on state-licensed medical marijuana.
UK-based biotech company Compass Pathways said Friday it has received an expedited review for its experimental form of synthetic psilocybin for treatment-resistant depression. In a press release the company cited two large, phase 3 studies that had "generated positive data." Usona Institute, headquartered in Wisconsin, also said it's received a voucher for its work with psilocybin to treat major depressive disorder. In an email, a Usona spokesperson said the company expects the review process to last one to two months after it submits its application. "The voucher expedites the timeline only; it does not alter scientific or regulatory standards," the spokesperson wrote. New York-based Transcend Therapeutics has also been granted a priority review voucher for its experimental drug methylone for PTSD, Blake Mandell, the company's chief executive officer, said. "There's a battle still raging in their mind that we don't fully understand biochemically," FDA Commissioner Marty Makary said. "When you see something that looks promising for a community that is suffering with mental health illness, despair and suicidal ideation, you can't help but recognize that."
Makary told NBC News that with the priority voucher program, the agency could potentially approve the first psychedelic drug by the end of summer.
UK-based biotech company Compass Pathways said Friday it has received an expedited review for its experimental form of synthetic psilocybin for treatment-resistant depression. In a press release the company cited two large, phase 3 studies that had "generated positive data." Usona Institute, headquartered in Wisconsin, also said it's received a voucher for its work with psilocybin to treat major depressive disorder. In an email, a Usona spokesperson said the company expects the review process to last one to two months after it submits its application. "The voucher expedites the timeline only; it does not alter scientific or regulatory standards," the spokesperson wrote. New York-based Transcend Therapeutics has also been granted a priority review voucher for its experimental drug methylone for PTSD, Blake Mandell, the company's chief executive officer, said. "There's a battle still raging in their mind that we don't fully understand biochemically," FDA Commissioner Marty Makary said. "When you see something that looks promising for a community that is suffering with mental health illness, despair and suicidal ideation, you can't help but recognize that."
Makary told NBC News that with the priority voucher program, the agency could potentially approve the first psychedelic drug by the end of summer.
Read more of this story at Slashdot.
​De grote natuurbrand bij 't Harde is onder controle. De brandweer heeft besloten Nederland gecontroleerd te laten uitbranden.
"Voor Nederlandse begrippen is dit een extreem grote brand", legt Landelijk Coördinator Natuurbrandbeheersing Edwin Kok uit. "Het klinkt misschien heftig, maar dan is dit toch echt de beste oplossing. Op deze manier kunnen we voorkomen dat de brand overslaat naar bijvoorbeeld België of de Noordzee."
Er is geen NL Alert verstuurd. Nederlanders moeten stilzitten en hun lot accepteren.
​
&
